Skip to main content
    E

    Eli Lilly and Company (LLY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $1433.55
    -9.95 (-0.69%)

    Market Cap: $1.29T

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Eli Lilly and Company (LLY) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Eli Lilly and Company (LLY) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Eli Lilly and Company reported EPS of $7.48, above the $5.38 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(28/40)
    Avg Surprise
    +11.51%
    Streak
    6 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$11.28
    Range$10.15 - $13.04
    21 analysts
    Revenue Consensus
    $24.84B
    Range$23.34B - $27.10B
    18 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$10.94
    Range$10.31 - $11.63
    6 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$9.94+10.1%
    60d ago$9.73+12.4%
    30d ago$9.96+9.9%
    7d ago$10.46+4.5%
    Current$10.94
    Revenue Consensus
    $23.55B
    Range$22.64B - $24.60B
    5 analysts

    Next Report

    LLY has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 49.6% above the $7.54 reported for the quarter ended Dec 31, 2025.

    LLY Earnings Call

    The latest LLY earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, LLY beat 28, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $24.40B, up 38.6% from $17.60B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$7.48$5.38$4.65 - $10.68+39.03%Beat+6.6%193 up, 7 downOct 29, 2026$24.40B
    Jun 30, 2026$8.38$6.01$5.28 - $9.08+39.43%Beat+32.8%200 up, 16 downAug 5, 2026$22.97B
    Mar 31, 2026$8.55$6.79$3.11 - $7.55+25.92%Beat+156.0%222 up, 13 downApr 30, 2026$19.80B
    Dec 31, 2025$7.54$7.17$6.16 - $7.86+5.16%Beat+41.7%194 up, 9 downFeb 4, 2026$19.29B
    Sep 30, 2025$7.02$5.89$5.49 - $7.21+19.19%Beat+494.9%190 up, 12 downOct 30, 2025$17.60B
    Jun 30, 2025$6.31$5.61$5.27 - $5.92+12.48%Beat+61.0%198 up, 6 downAug 7, 2025$15.56B
    Mar 31, 2025$3.34$3.46$2.68 - $5.36-3.47%Miss+29.5%170 up, 9 downMay 1, 2025$12.73B
    Dec 31, 2024$5.32$5.07$4.68 - $5.44+5.00%Beat+113.7%160 up, 12 downFeb 6, 2025$13.53B
    Sep 30, 2024$1.18$1.47$1.17 - $1.86-19.73%Miss+1080.0%150 up, 0 downOct 30, 2024$11.44B
    Jun 30, 2024$3.92$2.77$2.22 - $3.22+41.52%Beat+85.8%92 up, 1 downAug 8, 2024$11.30B
    Mar 31, 2024$2.58$2.49$2.22 - $2.78+3.61%Beat+59.3%162 up, 1 downApr 30, 2024$8.77B
    Dec 31, 2023$2.49$2.37$2.04 - $2.56+5.06%Beat+19.1%130 up, 1 downFeb 6, 2024$9.35B
    Sep 30, 2023$0.10-$0.12-$0.90 - $0.35+183.33%Beat-94.9%101 up, 1 downNov 2, 2023$9.50B
    Jun 30, 2023$2.11$1.99N/A+6.03%Beat+68.8%176 up, 1 downAug 8, 2023$8.31B
    Mar 31, 2023$1.62$1.73$1.32 - $1.92-6.36%Miss-38.2%174 up, 2 downApr 27, 2023$6.96B
    Dec 31, 2022$2.09$1.83$1.60 - $2.10+14.21%Beat-16.1%161 up, 2 downFeb 2, 2023$7.30B
    Sep 30, 2022$1.98$1.94$1.80 - $2.19+2.06%Beat+2.1%71 up, 0 downNov 1, 2022$6.94B
    Jun 30, 2022$1.25$1.70$1.48 - $1.84-26.47%Miss-33.2%83 up, 0 downAug 4, 2022$6.49B
    Mar 31, 2022$2.62$2.29$1.83 - $2.50+14.41%Beat+40.1%74 up, 0 downApr 28, 2022$7.81B
    Dec 31, 2021$2.49$2.51N/A-0.80%Miss-9.5%8N/AFeb 3, 2022$8.00B
    Sep 30, 2021$1.94$1.96N/A-1.02%Miss+26.0%6N/AOct 26, 2021$6.77B
    Jun 30, 2021$1.87$1.89$1.77 - $2.04-1.06%Miss-1.1%12N/AAug 3, 2021$6.74B
    Mar 31, 2021$1.87$2.10$1.98 - $2.35-10.95%Miss+6.9%11N/AApr 27, 2021$6.81B
    Dec 31, 2020$2.75$2.39$2.12 - $2.45+15.06%Beat+59.0%14N/AJan 29, 2021$7.44B
    Sep 30, 2020$1.54$1.71$1.50 - $1.84-9.94%Miss+4.1%12N/AOct 27, 2020$5.74B
    Jun 30, 2020$1.89$1.60$1.11 - $1.67+18.13%Beat+26.0%12N/AJul 30, 2020$5.50B
    Mar 31, 2020$1.75$1.48$1.17 - $1.68+18.24%Beat+31.6%11N/AApr 23, 2020$5.86B
    Dec 31, 2019$1.73$1.52$1.44 - $1.59+13.82%Beat+30.1%10N/AJan 30, 2020$6.11B
    Sep 30, 2019$1.48$1.41$1.25 - $1.45+4.96%Beat+6.5%10N/AOct 23, 2019$5.48B
    Jun 30, 2019$1.50$1.45$1.42 - $1.47+3.45%Beat0.0%10N/AJul 30, 2019$5.64B
    Mar 31, 2019$1.33$1.33$1.06 - $1.410.00%In line-0.7%11N/AApr 30, 2019$5.09B
    Dec 31, 2018$1.33$1.33$1.18 - $1.370.00%In line+16.7%12N/AFeb 6, 2019$5.64B
    Sep 30, 2018$1.39$1.35$1.19 - $1.42+2.96%Beat+32.4%12N/ANov 6, 2018$5.31B
    Jun 30, 2018$1.50$1.30$1.24 - $1.33+15.38%Beat+35.1%12N/AJul 24, 2018$5.58B
    Mar 31, 2018$1.34$1.13$1.08 - $1.18+18.58%Beat+36.7%16N/AApr 24, 2018$4.96B
    Dec 31, 2017$1.14$1.07$1.00 - $1.11+6.54%Beat+20.0%17N/AJan 31, 2018$3.26B
    Sep 30, 2017$1.05$1.03$0.98 - $1.07+1.94%Beat+19.3%18N/AOct 24, 2017$5.66B
    Jun 30, 2017$1.11$1.05$1.00 - $1.11+5.71%Beat+29.1%17N/AJul 25, 2017$5.82B
    Mar 31, 2017$0.98$0.96N/A+2.08%Beat+18.1%N/AN/AApr 25, 2017$5.23B
    Dec 31, 2016$0.95$0.98N/A-3.06%Miss+21.8%N/AN/AJan 31, 2017$5.76B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $24.21, up 86.2% from the year before. It was $3.52 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$24.21+86.2%
    Dec 31, 2024$13.00+105.7%
    Dec 31, 2023$6.32-20.4%
    Dec 31, 2022$7.94-2.8%
    Dec 31, 2021$8.17+3.0%
    Dec 31, 2020$7.93+31.3%
    Dec 31, 2019$6.04+8.6%
    Dec 31, 2018$5.56+29.9%
    Dec 31, 2017$4.28+21.6%
    Dec 31, 2016$3.52N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 24 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,47524
    2026Q2Jun 30, 20268,89422
    2026Q1Mar 31, 20268,16020
    2025Q4Dec 31, 20259,77523
    2025Q3Sep 30, 20258,71023
    2025Q2Jun 30, 20258,17122
    2025Q1Mar 31, 20259,52627
    2024Q4Dec 31, 20248,47824

    2026Q3 Earnings Call

    Opening remarks

    Michael Czapar Senior Vice President of Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q3 2026 earnings call. I am Michael Czapar, Senior Vice President of Investor Relations. Joining me on today's call are David A. Ricks, Lilly's chair and CEO; Lucas E. Montarce, chief financial officer; Dr. Daniel Skovronsky, chief scientific and medical officer; Adrienne Brown, president of Lilly Immunology; Dr. Carole Ho, president of Lilly Neuroscience; Ilya Yuffa, president of Lilly USA and global customer capabilities; Jacob S. Van Naarden, president of Lilly Oncology and head of business development; Patrik Jonsson, president of Lilly International; and Kenneth Custer, president of Lilly Cardiometabolic Health. During this call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide 4. Additional information concerning factors that could cause actual results to differ is contained in our latest Form 10-Ks and subsequent filings with the SEC. Information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional or otherwise influence prescribing decisions. Our commentary will focus on our non-GAAP financial measures. Now I will turn the call over to David.

    David A. Ricks Chair and CEO Thank you, Mike. Q3 was another quarter of solid execution. We delivered strong financial results, raised our full-year financial guidance, advanced our pipeline, and expanded our manufacturing footprint. Revenue grew nearly $7 billion compared to Q3 2025, and our key product revenue increased by over $6 billion. Within key products, revenue from our oncology, immunology, and neuroscience portfolio doubled versus last year. We continued the global rollout of Foundayo, launching in the UK, Mexico, and Saudi Arabia for people with obesity, and in Mexico for people with type 2 diabetes. We achieved several key regulatory and pipeline milestones since our last call, including the U.S. approval of our new weekly insulin and new indications for Inluriyo, Jaypirca, and Mounjaro. As part of the Medicare GLP-1 Bridge Program, we expanded access to obesity medicines in the U.S. for approximately 20 million seniors. Since the July 1 launch, more than half a million people have filled a prescription for a Lilly medicine through this program. We have heard positive feedback from patients and physicians about the initial implementation. Within the GLP-1 Bridge Program, the Lilly portfolio is performing well. Among new Bridge patients, 7 out of 10 are starting on a Lilly obesity medicine. We are encouraged to see the strong uptake of the Bridge Program and believe it has the potential to both improve outcomes for seniors and save costs for Medicare.

    Frequently Asked Questions About LLY

    When is Eli Lilly and Company's next earnings date?

    Eli Lilly and Company's next earnings report is expected for Feb 2, 2027.

    Did LLY beat earnings estimates last quarter?

    Yes. Eli Lilly and Company reported EPS of $7.48 for the quarter ended Sep 30, 2026, above the $5.38 estimate, a 39.03% surprise.

    What EPS do analysts expect from LLY next quarter?

    The consensus EPS estimate for Eli Lilly and Company for the quarter ending Dec 31, 2026 is $11.28 from 21 analysts, with estimates from $10.15 to $13.04.

    How often does LLY beat earnings estimates?

    Eli Lilly and Company beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +17.84%.